163 related articles for article (PubMed ID: 20728763)
1. Cost-effectiveness of stockpiling 23-valent pneumococcal polysaccharide vaccine to prevent secondary pneumococcal infections among a high-risk population in the United States during an influenza pandemic.
Dhankhar P; Grabenstein JD; O'Brien MA; Dasbach EJ
Clin Ther; 2010 Aug; 32(8):1501-16. PubMed ID: 20728763
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions.
Cho BH; Stoecker C; Link-Gelles R; Moore MR
Vaccine; 2013 Dec; 31(50):6011-21. PubMed ID: 24148572
[TBL] [Abstract][Full Text] [Related]
3. Results of a cohort model analysis of the cost-effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged > or =65 years in the Netherlands.
Rozenbaum MH; Hak E; van der Werf TS; Postma MJ
Clin Ther; 2010 Aug; 32(8):1517-32. PubMed ID: 20728764
[TBL] [Abstract][Full Text] [Related]
4. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23).
;
MMWR Morb Mortal Wkly Rep; 2010 Sep; 59(34):1102-6. PubMed ID: 20814406
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
[TBL] [Abstract][Full Text] [Related]
6. New vaccines against otitis media: projected benefits and cost-effectiveness.
O'Brien MA; Prosser LA; Paradise JL; Ray GT; Kulldorff M; Kurs-Lasky M; Hinrichsen VL; Mehta J; Colborn DK; Lieu TA
Pediatrics; 2009 Jun; 123(6):1452-63. PubMed ID: 19482754
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales.
Melegaro A; Edmunds WJ
Vaccine; 2004 Oct; 22(31-32):4203-14. PubMed ID: 15474710
[TBL] [Abstract][Full Text] [Related]
8. [Economic evaluation of an infant immunization program in Mexico, based on 13-valent pneumococcal conjugated vaccines].
Muciño-Ortega E; Mould-Quevedo JF; Farkouh R; Strutton D
Value Health; 2011; 14(5 Suppl 1):S65-70. PubMed ID: 21839902
[TBL] [Abstract][Full Text] [Related]
9. Pneumococcal pneumonia and influenza: a deadly combination.
Klugman KP; Chien YW; Madhi SA
Vaccine; 2009 Aug; 27 Suppl 3():C9-C14. PubMed ID: 19683658
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of influenza and pneumococcal vaccination for Hong Kong elderly in long-term care facilities.
You JH; Wong WC; Ip M; Lee NL; Ho SC
J Epidemiol Community Health; 2009 Nov; 63(11):906-11. PubMed ID: 19608558
[TBL] [Abstract][Full Text] [Related]
11. The health and economic impact of vaccination with 7-valent pneumococcal vaccine (PCV7) during an annual influenza epidemic and influenza pandemic in China.
Caldwell R; Roberts CS; An Z; Chen CI; Wang B
BMC Infect Dis; 2015 Jul; 15():284. PubMed ID: 26206275
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects.
Ray GT; Whitney CG; Fireman BH; Ciuryla V; Black SB
Pediatr Infect Dis J; 2006 Jun; 25(6):494-501. PubMed ID: 16732146
[TBL] [Abstract][Full Text] [Related]
13. An economic analysis of a pneumococcal vaccine programme in people aged over 64 years in a developed country setting.
Mangtani P; Roberts JA; Hall AJ; Cutts FT
Int J Epidemiol; 2005 Jun; 34(3):565-74. PubMed ID: 15764694
[TBL] [Abstract][Full Text] [Related]
14. [Vaccination of the elderly against pneumococcal disease is cost-efficient. Mass vaccination of all aged 65 and over is recommended].
Ortqvist A; Jönsson B; Baltussen R; Ament A
Lakartidningen; 2000 Nov; 97(45):5120-5. PubMed ID: 11116891
[TBL] [Abstract][Full Text] [Related]
15. Higher pneumococcal disease vaccination rates needed to protect more at-risk US adults.
Rehm SJ; Farley MM; File TM; Hall WJ; Hopkins R; Levine OS; Nichol KL; Nuorti P; Zimmerman RK; Schaffner W
Postgrad Med; 2009 Nov; 121(6):101-5. PubMed ID: 19940420
[TBL] [Abstract][Full Text] [Related]
16. [Pharmaco-economic aspects of vaccination against invasive pneumococcal infections in persons over 65 years of age; review of the literature on cost effectiveness analysis].
Postma MJ; Heijnen ML; Beutels P; Jager JC
Ned Tijdschr Geneeskd; 2002 May; 146(18):855-9. PubMed ID: 12038224
[TBL] [Abstract][Full Text] [Related]
17. The cost-burden of paediatric pneumococcal disease in Sweden and the potential cost-effectiveness of prevention using 7-valent pneumococcal vaccine.
Silfverdal SA; Berg S; Hemlin C; Jokinen I
Vaccine; 2009 Mar; 27(10):1601-8. PubMed ID: 19146905
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of a 3-dose pneumococcal conjugate vaccine program in the province of Quebec, Canada.
Poirier B; De Wals P; Petit G; Erickson LJ; Pépin J
Vaccine; 2009 Nov; 27(50):7105-9. PubMed ID: 19786137
[TBL] [Abstract][Full Text] [Related]
19. The number needed to vaccinate (NNV) and population extensions of the NNV: comparison of influenza and pneumococcal vaccine programmes for people aged 65 years and over.
Kelly H; Attia J; Andrews R; Heller RF
Vaccine; 2004 Jun; 22(17-18):2192-8. PubMed ID: 15149776
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects.
Lloyd A; Patel N; Scott DA; Runge C; Claes C; Rose M
Eur J Health Econ; 2008 Feb; 9(1):7-15. PubMed ID: 17333089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
